Drug

Ifebemtinib clinical trials

Also written BI 853520 and IN10018.

studies test it: 10
open now: 5
in phase 3: 0
first study started: 2011

Keep track of what changes. Save the ifebemtinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

BI 853520: 8
IN10018: 6

Combined with it in one product

HX009+IN10018: 1

Studies by the year they started

10 studies that test it; most in 2022 (3)

Studies that test ifebemtinib, by start year
Year	Studies
2011	1
2013	1
2022	3
2023	2
2025	3

By phase

A phase 1/2 study counts in both.

Phase 1: 8
Phase 2: 8

What it is tested for

Each study’s main condition, where its own words name it.

Biliary Tract Neoplasms: 1
Small Cell Lung Carcinoma: 1
Ovarian Neoplasms: 1

Who runs them

Industry 9 · Other 1

InxMed (Shanghai) Co., Ltd. (5) · Boehringer Ingelheim (2) · InventisBio Co., Ltd (1) · Hangzhou Hanx Biopharmaceuticals, Ltd. (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)

Often tested with

Tested in the same studies.

Garsorasib (1) · Anti-PD-1/CD47 Fusion Protein HX009 (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Cadonilimab (1)

Studies

Open first, then newest update. How each study uses ifebemtinib is read from its arms, and is right about nine times in ten.

Testing it · 10

Given in every arm · 5 — ifebemtinib is usual care beside what is tested

Codes

What other systems call ifebemtinib · ClinicalTrials.gg INT016181

UNII (FDA) C57O858DKUIFEBEMTINIBOne source FDA
NCI Thesaurus C166122IfebemtinibOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	C57O858DKU	IFEBEMTINIB	One source FDA
NCI Thesaurus	C166122	Ifebemtinib	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.